Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;20(1):45-56.
doi: 10.1080/17460913.2024.2428526. Epub 2024 Nov 15.

Treatment outcome in patients with spinal neurocysticercosis: a systematic review of published cases and case series

Ravindra Kumar Garg  1 , Imran Rizvi  1 , Harish Nigam  1 , Shweta Pandey  1 , Ravi Uniyal  1
Affiliations

Treatment outcome in patients with spinal neurocysticercosis: a systematic review of published cases and case series

Ravindra Kumar Garg et al. Future Microbiol. 2025 Jan.

Abstract

Aims: Spinal neurocysticercosis is a rare central nervous system infection caused by the larval form of the Taenia solium. Due to its rarity, most knowledge is derived from isolated case reports. This review aims to evaluate existing case reports and observational studies to provide a comprehensive overview of the disease's clinical presentation and treatment outcomes.

Methods: Following PRISMA guidelines, a comprehensive search was performed across various databases. The review included case reports, case series, and observational studies, and it is registered with PROSPERO (CRD42024496957).

Results: This review analyzed 206 spinal neurocysticercosis cases (from 171 published reports). Symptoms persisted for one week to six months in 49% of cases, and common presentations included paraparesis/quadriparesis (61.7%) and neck/limb/back pain (40.8%). CSF abnormalities were observed in 23.8%. Thoracic involvement was most frequent (39.3%), followed by cervical (27.2%). Neurocysticercosis lesions in other regions, primarily the brain, were found in 18.9%. Differential diagnoses included spinal cord tumors (13.1%). Treatment often involved surgery alone (32%) or with cysticidal drugs (45.6%), with a 91.3% improvement rate, indicating favorable outcomes.

Conclusions: Spinal neurocysticercosis primarily affects the thoracic and cervical regions. Most patients respond well to medical therapy; surgery is mainly for progressive neurological deficits.

Keywords: Cysticercosis; Taenia solium; albendazole; myelopathy; spinal cord.

Plain language summary

Neurocysticercosis is an infection caused by the larvae of a tapeworm called Taenia solium entering the body. This tapeworm is common in areas with poor sanitation and hygiene, where people often have contact with contaminated food or water. Once ingested, the larvae travel through the bloodstream to various parts of the body, including the muscles, skin, eyes, spinal cord and the brain. In the brain or spinal cord, the larvae can cause severe symptoms. To diagnose neurocysticercosis, doctors often use imaging tests that show the cysts that form in the nervous system. In our study, we looked at a group of patients who had spinal neurocysticercosis to understand their symptoms, how they were diagnosed and how effective different treatments are. Most patients had weakness in the legs or lower body and ongoing back pain. Many patients were first treated with surgery to remove the cysts from the spinal cord. We found that medications to kill the tapeworm larvae, known as antiparasitic or anti-worm medicines, were often just as effective. This means that surgery could be avoided in many cases if medications are used instead.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization . Taeniasis/Cysticercosis. Key facts. 2022. Jan 11 [cited 2024 Jan 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/taeniasis-cysticercosis
    1. World Health Organization . WHO guidelines on the management of Taenia solium neurocysticercosis. Technical document; 2021. Sep 2 [cited 2024 Jan 21]. Available from: https://www.who.int/publications/i/item/9789240032231 - PubMed

    2. •• This article is important for providing WHO’s official guidelines on managing Taenia solium neurocysticercosis worldwide.

    1. Owolabi LF, Adamu B, Jibo AM, et al. Neurocysticercosis in people with epilepsy in Sub-Saharan Africa: a systematic review and meta-analysis of the prevalence and strength of association. Seizure. 2020;76:1–11. doi: 10.1016/j.seizure.2020.01.005 - DOI - PubMed
    1. Garcia HH. Neurocysticercosis. Neurol Clin. 2018. Nov;36(4):851–864. doi: 10.1016/j.ncl.2018.07.003 - DOI - PubMed
    1. Del Brutto OH. Human neurocysticercosis: an overview. Pathogens. 2022;11(10):1212. doi: 10.3390/pathogens11101212 - DOI - PMC - PubMed

    2. • This article is important for its comprehensive overview of human neurocysticercosis, highlighting pathogenesis and clinical features.

Publication types

LinkOut - more resources